Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 80

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 80
---
 fat-based
particles called liposomes to carry powerful medicines directly to where they’re needed in the body. We believe that this method
is one of the more advanced ways to deliver medicine and allows the drugs to stay in the bloodstream longer, reach their target more
precisely, and release their effects in a controlled way. We believe that this approach is designed to improve drug delivery and treatment
outcomes, subject to validation in clinical studies. At Revium Rx, we’re leveraging these features to target diseased tissues,
including tumors and infected areas, thereby minimizing effects on healthy cells.

We are developing a portfolio of lipid based
and Nano-Liposomal Particle NLP-based pharmaceutical candidates and plan to complete the development and commercialization of a series
of medical technologies comprised of:

| ● | A nanoparticle-based formulation                                                                                                            
 of mupirocin, a well-known and potent antibiotic currently limited to topical use due to its instability in blood when administered         
 systemically. Our novel Nano-Mupirocin formulation, supported by both in vitro and in vivo animal studies, has demonstrated promising       
 potential for the treatment of severe, life-threatening infections caused by antibiotic-resistant bacteria, including Methicillin-Resistant 
 Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococci (VRE), and Neisseria gonorrhoeae.   If approved, the novel                   
 proprietary formulation of nano-mupirocin is intended to be administered systemically, providing extended presence in the bloodstream       
 and enhanced delivery of mupirocin to inflamed areas of the body.                                                                           |

| ● | A novel                                                                                                                                     
 combination therapy designed to enhance the efficacy of existing cancer treatments: our novel nanoparticle-based formulation of angiotensin 
 receptor blockers (ARB), Nano-Candesartan, is being developed for intravenous administration, and is intended to improve treatment          
 outcomes when used in combination with established anticancer therapies, with an initial focus on pancreatic cancer indication. See         
 below Description of Business, Our Second Lead Candidate, Nano-Candesartan (nanoparticles-based ARB), is targeted for combination           
 therapy with an initial indication in pancreatic ductal adenocarcinoma (PDAC).                                                              |

| ● | Liposomal Protein-Loaded Technology (LPLT), which is currently in early-stage development, represents a novel approach to immunization through innovative nanoparticle-based vaccines. We are currently awaiting the completion by Prof. Barenholz of a SARS-CoV-2 challenge